You just read:

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hypophosphatemia in Children

News provided by

Kyowa Kirin International PLC

23 Feb, 2018, 13:00 GMT